Evidence map›Paper›PMID 38433672›Full record

ArticleThe Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics2023

Ameet Sarpatwari

Abstract read
PubMed Publisher
In one paragraph

Article in The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Rupturing the Temporality of Pharmaceutical Patents: A Sketch for a New Temporal Economy of Pharmaceutical Markets.The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics · 2025
    Article
  2. The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics · 2023
    Article
4 · The record

Corrections and comments

  • Commented on by
    2023
  • Commented on by
    2023
5 · Who and what money

Authors and funding

1 author.

Ameet Sarpatwari

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In January 2023, Moderna announced its intent to increase the price of the COVID-19 vaccine it co-developed with the National Institutes of Health (NIH) by 400%. The federal government should pressure Moderna to change course and resume buying doses for all Americans, leveraging its purchasing power to obtain a fair price.

Indexed as

COVID-19 VaccinesIntentionFederal GovernmentHumansInvestmentsNational Institutes of Health (U.S.)United StatesCOVID-19 VaccinesCOVID-19mRNA VaccinesPatient CostsPublic FundingTechnology Transfer

Identifiers

PMID38433672

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.